D28L001 is a first-in-class bispecific aptamer targeting VEGF and IL-8 — two pathways that synergistically drive disease across ophthalmology. Our multi-indication strategy maximizes platform value while mitigating single-indication risk.
| Indication | Stage | Development Progress | Market Size | Unmet Need |
|---|---|---|---|---|
| Retinal Detachment / PVR Lead | Preclinical |
Discovery → Lead Opt → Preclinical → IND → Ph I/II → Ph III
|
$122–202M peak US | ★★★★★ |
| Neovascular AMD Tier 2 | Lead Optimization |
Discovery → Lead Opt → Preclinical → IND → Ph I/II → Ph III
|
$7.5–8.5B global | ★★★☆☆ |
| Diabetic Macular Edema Tier 2 | Lead Optimization |
Discovery → Lead Opt → Preclinical → IND → Ph I/II → Ph III
|
$4.5–5.0B global | ★★★★☆ |
PVR is the #1 cause of retinal detachment surgical failure. After 50+ years of vitrectomy, there is still zero approved pharmacotherapy. D28L001 would create and own the category.
Proliferative vitreoretinopathy (PVR) develops in 5–10% of retinal detachment repairs, causing scar tissue to re-detach the retina. Once PVR develops, an eye needs nearly four operations instead of fewer than two, with twice the clinic visits and hours under anesthesia (Patel 2004). PVR is driven by IL-8-mediated inflammation and VEGF-dependent angiogenesis — both targets of D28L001.
Unlike nAMD/DME where D28L001 would compete against established anti-VEGF agents, RD/PVR is a completely uncontested market. Smaller, faster clinical trials are possible due to the acute dosing paradigm (1–2 injections per surgical episode vs. chronic monthly injections). Potential for Breakthrough Therapy Designation and Priority Review could accelerate approval by 1–2 years.
| Factor | AMD / DME Indication | RD / PVR Indication |
|---|---|---|
| Competition | Intense — Eylea, Vabysmo, biosimilars | None — zero approved therapies |
| Unmet Need | Moderate — good drugs exist, durability needed | Extreme — no drug exists at all |
| Dosing | Chronic (years of treatment) | Acute (1–2 injections per surgery) |
| Trial Size | Large Phase III (1,000+ patients) | Smaller trials possible (300–500 patients) |
| Differentiation | Primarily durability advantage | Triple: mechanism + durability + anti-fibrotic |
| Price Sensitivity | High (biosimilar pressure) | Low (surgical adjunct, no alternatives) |
| D28L001 Advantage | Strong — addresses IL-8 escape pathway | Overwhelming — creates new category |
The $7.5–8.5 billion nAMD market is dominated by anti-VEGF monotherapies — but a meaningful share of patients show incomplete response. D28L001 targets the IL-8 inflammatory pathway that current therapies leave unaddressed.
Despite the success of anti-VEGF agents in nAMD, a significant proportion of patients show suboptimal response. IL-8 drives VEGF-independent angiogenesis, acting as an escape pathway when VEGF alone is inhibited. Chronic anti-VEGF therapy can trigger compensatory IL-8 upregulation. Current agents have no mechanism to address this inflammatory cascade.
The nAMD program shares the identical intravitreal formulation, GLP toxicology package, and manufacturing process with the RD/PVR lead program. This means substantially reduced development cost and timeline — leveraging the RD/PVR IND-enabling data directly into a nAMD Phase I study targeting anti-VEGF incomplete responders. A single FDA Pre-IND meeting can cover both indications.
| Agent | Mechanism | Dosing | IL-8 Pathway? |
|---|---|---|---|
| Aflibercept (Eylea) | Anti-VEGF/PlGF | Q4–8w | ✕ No |
| Ranibizumab (Lucentis) | Anti-VEGF | Q4w | ✕ No |
| Faricimab (Vabysmo) | Anti-VEGF + anti-Ang-2 | Q8–16w | ✕ No (targets Ang-2, not IL-8) |
| Brolucizumab (Beovu) | Anti-VEGF | Q8–12w | ✕ No |
| D28L001 | Anti-VEGF + anti-IL-8 | Q12–24w (predicted) | ✓Yes — first and only |
The global diabetes epidemic is driving DME cases higher. Around 40% of DME eyes show a suboptimal early response to anti-VEGF therapy — and IL-8 is a key driver of that resistance. D28L001 offers targeted anti-inflammatory benefit without steroid toxicity.
Meta-analysis confirms that IL-8 is significantly elevated in the aqueous humor of DME eyes. Current anti-VEGF agents suppress VEGF but leave IL-8 and other inflammatory mediators untreated. The only existing anti-inflammatory option — corticosteroids — carries unacceptable side effects (IOP elevation, cataract formation). D28L001's anti-IL-8 component provides targeted anti-inflammatory benefit without steroid toxicity.
Global diabetes prevalence is projected to reach 783 million by 2045 (IDF). With approximately 7–10% of diabetic patients developing DME, the addressable population is growing faster than any other retinal indication. D28L001's differentiated mechanism positions it to capture significant share in this expanding market — particularly as anti-VEGF resistance becomes an increasingly recognized clinical challenge.
Once established in primary RD/PVR, D28L001 can expand into adjacent surgical and medical retinal indications — on the same intraoperative paradigm, before the AMD/DME office-injection opportunity — carried at zero in the current valuation and sized separately as the program advances.
High IL-8/VEGF environment with elevated PVR risk. Direct label expansion from primary RD/PVR data.
VEGF + IL-8 driven; frequently requires vitrectomy. Phase II/III expansion study from RD/PVR approval.
Post-vitrectomy inflammation and CME driven by IL-8. Off-label use initially; Phase IV study supports label.
Maximum inflammatory response with very high PVR risk. Supplemental NDA pathway from base RD/PVR approval.
Fibrotic membrane formation driven by IL-8/EMT pathways — directly aligned with D28L001 mechanism.
Global myopia projected to reach 4.8B by 2050 (from 2.6B in 2020). High myopia is the leading RD risk factor.
First-in-class bispecific aptamer. Three indications. $12B+ combined market. Zero approved competitors in the lead indication. $1.74M raised to date ($1.32M non-dilutive grant capital).